Overview

Vaccine Contract Manufacturing Market is poised to value over USD 4.4 billion by 2027 end at a CAGR of over 9.3% during the forecast period 2020 to 2027.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Vaccine Contract Manufacturing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Vaccine Contract Manufacturing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Vaccine Contract Manufacturing Market:
• Lonza
• Fujifilm Diosynth Biotechnologies U.S.A., Inc.
• Ajinomoto Althea, Inc.
• Merck KGaA
• Servier Laboratories (France)
• Pfizer Inc. (US)
• Mereck KGaA (Germany)
• Cytovance Biologics
• Catalent, Inc.
• IDT Biologika
• PRA Health Sciences
• Icon plc.
• Pharmaceutical Product Development, LLC
• Cobra Bio
• Paragon Bioservices, Inc.
• KBI Biopharma
• Goodwin Biotechnology, Inc
(Note: The list of the major players will be updated with the latest market scenario and trends)

Vaccine Contract Manufacturing Market Segmentation:
By Vaccine Type
• Attenuated Vaccine
• Inactivated Vaccine
• Subunit vaccines
• Toxoid Vaccines
• DNA Vaccines

By Workflow
• Downstream
 o Fill & Finish Operations
 o Analytical & QC studies
 o Packaging
• Upstream
 o Mammalian Expression Systems
 o Bacterial Expression Systems
 o Yeast Expression Systems
 o Baculovirus/Insect Expression Systems
 o Others
 
By Application
• Human Use
• Veterinary

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Vaccine Contract Manufacturing Market By Vaccine Type, By Workflow, By Application and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- Vaccine Type launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Global Vaccine Contract Manufacturing Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Vaccine Contract Manufacturing Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Vaccine Contract Manufacturing Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Global Vaccine Contract Manufacturing Market,By Vaccine Type Historical Analysis and Forecast 2020-2027 (USD Million)
  7.1. Attenuated Vaccine
  7.2. Inactivated Vaccine
  7.3. Subunit vaccines
  7.4. Toxoid Vaccines
  7.5. DNA Vaccines

8. Global Vaccine Contract Manufacturing Market,By Workflow Historical Analysis and Forecast 2020-2027 (USD Million)  
  8.1. Downstream
       8.1.1. Fill & Finish Operations
       8.1.2. Analytical & QC studies
       8.1.3. Packaging
  8.2. Upstream
       8.2.1. Mammalian Expression Systems
       8.2.2. Bacterial Expression Systems
       8.2.3. Yeast Expression Systems
       8.2.4. Baculovirus/Insect Expression Systems
       8.2.5. Others
     
9. Global Vaccine Contract Manufacturing Market,By Application Historical Analysis and Forecast 2020-2027 (USD Million)  
  9.1. Human Use
  9.2. Veterinary
 
10. North America Vaccine Contract Manufacturing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
  10.1. Introduction
  10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
       10.2.1. U.S.A
       10.2.2. Canada
       10.2.3. Mexico
  10.3. Market Size (USD Million) Forecast for North America 2020-2027

11. Latin America Vaccine Contract Manufacturing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   11.1. Introduction
   11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         11.2.1. Brazil
         11.2.2. Venezuela
         11.2.3. Argentina
         11.2.4. Rest of Latin America
   11.3. Market Size (USD Million) Forecast for Latin America 2020-2027

12. Europe Vaccine Contract Manufacturing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         12.2.1. Germany
         12.2.2. U.K        
         12.2.3. France
         12.2.4. Italy
         12.2.5. Spain
         12.2.6. Russia
         12.2.7. Poland
         12.2.8. Rest of Europe
   12.3. Market Size (USD Million) Forecast for Europe 2020-2027

13. Asia Pacific Vaccine Contract Manufacturing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   13.1. Introduction
   13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         13.2.1. Japan
         13.2.2. China
         13.2.3. India
         13.2.4. Australia and New Zealand
         13.2.5. ASEAN
         13.2.6. Rest of Asia Pacific
   13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027  

14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   14.1. Introduction
   14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         14.2.1. Saudi Arabia
         14.2.2. UAE
         14.2.3. South Africa
         14.2.4. Egypt
   14.3. Market Size (USD Million) Forecast for MEA 2020-2027

15. Market Share Analysis and Competitive Landscape  
   15.1. Global Landscape - Key Players, Revenue and Presence
   15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   15.3. Global Emerging Companies
   15.4.  North America - Market Share Analysis and Key Regional Players
   15.5.  Europe - Market Share Analysis and Key Regional Players
   15.6.  Asia Pacific - Market Share Analysis and Key Regional Players
   15.7.  Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Vaccine Types Offered and Financial Layouts)
   16.1. Lonza
         16.1.1. Company Overview
         16.1.2. Vaccine Type Portfolio
         16.1.3. SWOT Analysis
         16.1.4. Financial Overview
         16.1.5. Strategic Overview
   16.2. Fujifilm Diosynth Biotechnologies U.S.A., Inc.
         16.2.1. Company Overview
         16.2.2. Vaccine Type Portfolio
         16.2.3. SWOT Analysis
         16.2.4. Financial Overview
         16.2.5. Strategic Overview
   16.3. Ajinomoto Althea, Inc.
         16.3.1. Company Overview
         16.3.2. Vaccine Type Portfolio
         16.3.3. SWOT Analysis
         16.3.4. Financial Overview
         16.3.5. Strategic Overview
   16.4. Merck KGaA
         16.4.1. Company Overview
         16.4.2. Vaccine Type Portfolio
         16.4.3. SWOT Analysis
         16.4.4. Financial Overview
         16.4.5. Strategic Overview
   16.5. Cytovance Biologics
         16.5.1. Company Overview
         16.5.2. Vaccine Type Portfolio
         16.5.3. SWOT Analysis
         16.5.4. Financial Overview
         16.5.5. Strategic Overview          
   16.6. Catalent, Inc.
         16.6.1. Company Overview
         16.6.2. Vaccine Type Portfolio
         16.6.3. SWOT Analysis
         16.6.4. Financial Overview
         16.6.5. Strategic Overview      
   16.7. IDT Biologika
         16.7.1. Company Overview
         16.7.2. Vaccine Type Portfolio
         16.7.3. SWOT Analysis
         16.7.4. Financial Overview
         16.7.5. Strategic Overview
   16.8. Albany Molecular Research, Inc.
         16.8.1. Company Overview
         16.8.2. Vaccine Type Portfolio
         16.8.3. SWOT Analysis
         16.8.4. Financial Overview
         16.8.5. Strategic Overview
   16.9. PRA Health Sciences
         16.9.1. Company Overview
         16.9.2. Vaccine Type Portfolio
         16.9.3. SWOT Analysis
         16.9.4. Financial Overview
         16.9.5. Strategic Overview
   16.10.Icon plc.
         16.10.1. Company Overview
         16.10.2. Vaccine Type Portfolio
         16.10.3. SWOT Analysis
         16.10.4. Financial Overview
         16.10.5. Strategic Overview
   16.11.Pharmaceutical Product Development, LLC
         16.11.1. Company Overview
         16.11.2. Vaccine Type Portfolio
         16.11.3. SWOT Analysis
         16.11.4. Financial Overview
         16.11.5. Strategic Overview
   16.12.Cobra Bio
         16.12.1. Company Overview
         16.12.2. Vaccine Type Portfolio
         16.12.3. SWOT Analysis
         16.12.4. Financial Overview
         16.12.5. Strategic Overview
   16.13.Paragon Bioservices, Inc.
         16.13.1. Company Overview
         16.13.2. Vaccine Type Portfolio
         16.13.3. SWOT Analysis
         16.13.4. Financial Overview
         16.13.5. Strategic Overview
   16.14.KBI Biopharma
         16.14.1. Company Overview
         16.14.2. Vaccine Type Portfolio
         16.14.3. SWOT Analysis
         16.14.4. Financial Overview
         16.14.5. Strategic Overview
   16.15.Goodwin Biotechnology, Inc
         16.15.1. Company Overview
         16.15.2. Vaccine Type Portfolio
         16.15.3. SWOT Analysis
         16.15.4. Financial Overview
         16.15.5. Strategic Overview
 
17. Pre and Post COVID-19 Impact
   17.1. Positive influence on the healthcare industry
   17.2. The financial disruption of the manufacturing sector
   17.3. Impact of COVID-19 on emerging companies
   17.4. Significant mandates in the healthcare regulations initiated by administrations
   17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures